ClinicalTrials.gg
CompletedNCT00134173ILLUSTRATEUpdated Dec 10, 2007

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Coronary Disease, Coronary Arteriosclerosis and Hyperlipidemia, sponsored by Pfizer. Completed at 147 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-12-10.

Primary conditionCoronary Artery DiseaseRegistry: Coronary DiseaseReclassifiedWhy we changed it
Registry
Coronary Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Coronary Artery Disease
Why
  1. The study's listed conditions name Coronary Artery Disease, a narrower term within Coronary Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 33 studies testing atorvastatin in Coronary Artery Disease — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Coronary Artery Disease.

Enrollment
2nd of 33
1,100 · median 120
Started
2003
with 4 others
Phase 3
8 of 33
none open now
Registered
1st of 33
by date
Lead sponsor
2 of 33
Pfizer

Among the 33 studies testing atorvastatin in Coronary Artery Disease, this one is the 2nd largest by enrollment, is one of 5 that started in 2003, is one of 8 in phase 3, and was the 1st registered.

Coronary Artery Disease

4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 33 studies testing atorvastatin in Coronary Artery Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing atorvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease

Read the detailed description

For additional information please call: 1-800-718-1021

03

Conditions studied

  • Coronary Disease
  • Coronary Arteriosclerosis
  • Hyperlipidemia

Browse trials for

04

In context

Coronary Artery Disease Reclassified

4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

This study's enrollment of 1,100 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronary Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • angiographic evidence of coronary atherosclerosis

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid.
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,100 participants

Interventions

07

What researchers measure

Primary outcomes

  1. Change coronary artery atheroma volume as measured by intravascular ultrasound.

Secondary outcomes

  1. Changes in levels of lipids and other biomarkers.

08

Study locations

147 sites
  • Pfizer Investigational Site
    Birmingham, Alabama, United States
  • Pfizer Investigational Site
    Mobile, Alabama, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas, United States
  • Pfizer Investigational Site
    Fresno, California, United States
  • Pfizer Investigational Site
    Los Altos, California, United States
  • Pfizer Investigational Site
    Los Angeles, California, United States
  • Pfizer Investigational Site
    Mountain View, California, United States
  • Pfizer Investigational Site
    Sacramento, California, United States
  • Pfizer Investigational Site
    San Diego, California, United States
  • Pfizer Investigational Site
    San Francisco, California, United States
  • Pfizer Investigational Site
    Santa Rosa, California, United States
  • Pfizer Investigational Site
    Stockton, California, United States
  • Pfizer Investigational Site
    Boulder, Colorado, United States
  • Pfizer Investigational Site
    Denver, Colorado, United States
  • Pfizer Investigational Site
    Brandford, Connecticut, United States
  • Pfizer Investigational Site
    Farmington, Connecticut, United States
  • Pfizer Investigational Site
    Guilford, Connecticut, United States
  • Pfizer Investigational Site
    New Haven, Connecticut, United States
  • Pfizer Investigational Site
    Atlantis, Florida, United States
  • Pfizer Investigational Site
    Clearwater, Florida, United States
  • Pfizer Investigational Site
    Dunedin, Florida, United States
  • Pfizer Investigational Site
    Fort Lauderdale, Florida, United States
  • Pfizer Investigational Site
    Jacksonville, Florida, United States
  • Pfizer Investigational Site
    Largo, Florida, United States
  • Pfizer Investigational Site
    Melbourne, Florida, United States
  • Pfizer Investigational Site
    Miami, Florida, United States
  • Pfizer Investigational Site
    Orlando, Florida, United States
  • Pfizer Investigational Site
    Pensacola, Florida, United States
  • Pfizer Investigational Site
    Safety Harbor, Florida, United States
  • Pfizer Investigational Site
    Sarasota, Florida, United States
  • Pfizer Investigational Site
    Tampa, Florida, United States
  • Pfizer Investigational Site
    Blue Island, Illinois, United States
  • Pfizer Investigational Site
    Merrionette Park, Illinois, United States
  • Pfizer Investigational Site
    Rockford, Illinois, United States
  • Pfizer Investigational Site
    Elkhart, Indiana, United States
  • Pfizer Investigational Site
    Goshen, Indiana, United States
  • Pfizer Investigational Site
    Hobart, Indiana, United States
  • Pfizer Investigational Site
    Merrillville, Indiana, United States
  • Pfizer Investigational Site
    Davenport, Iowa, United States
  • Pfizer Investigational Site
    Des Moines, Iowa, United States
  • Pfizer Investigational Site
    West Des Moines, Iowa, United States
  • Pfizer Investigational Site
    Shawnee Mission, Kansas, United States
  • Pfizer Investigational Site
    Louisville, Kentucky, United States
  • Pfizer Investigational Site
    Bogalusa, Louisiana, United States
  • Pfizer Investigational Site
    Covington, Louisiana, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana, United States
  • Pfizer Investigational Site
    Auburn, Maine, United States
  • Pfizer Investigational Site
    Lewiston, Maine, United States
  • Pfizer Investigational Site
    Portland, Maine, United States
  • Pfizer Investigational Site
    Scarborough, Maine, United States
  • Pfizer Investigational Site
    Baltimore, Maryland, United States
  • Pfizer Investigational Site
    Columbia, Maryland, United States
  • Pfizer Investigational Site
    Salisbury, Maryland, United States
  • Pfizer Investigational Site
    Takoma Park, Maryland, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan, United States
  • Pfizer Investigational Site
    Flint, Michigan, United States
  • Pfizer Investigational Site
    Kalamazoo, Michigan, United States
  • Pfizer Investigational Site
    Lapeer, Michigan, United States
  • Pfizer Investigational Site
    Petoskey, Michigan, United States
  • Pfizer Investigational Site
    Royal Oak, Michigan, United States
  • Pfizer Investigational Site
    Saginaw, Michigan, United States
  • Pfizer Investigational Site
    Ypsilanti, Michigan, United States
  • Pfizer Investigational Site
    Duluth, Minnesota, United States
  • Pfizer Investigational Site
    Maplewood, Minnesota, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota, United States
  • Pfizer Investigational Site
    St. Cloud, Minnesota, United States
  • Pfizer Investigational Site
    St. Paul, Minnesota, United States
  • Pfizer Investigational Site
    Southaven, Mississippi, United States
  • Pfizer Investigational Site
    Kansas City, Missouri, United States
  • Pfizer Investigational Site
    Omaha, Nebraska, United States
  • Pfizer Investigational Site
    Ridgewood, New Jersey, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico, United States
  • Pfizer Investigational Site
    Carlsbad, New Mexico, United States
  • Pfizer Investigational Site
    Albany, New York, United States
  • Pfizer Investigational Site
    Bay Shore, New York, United States
  • Pfizer Investigational Site
    Buffalo, New York, United States
  • Pfizer Investigational Site
    Flushing, New York, United States
  • Pfizer Investigational Site
    Johnson City, New York, United States
  • Pfizer Investigational Site
    New York, New York, United States
  • Pfizer Investigational Site
    Oneonta, New York, United States
  • Pfizer Investigational Site
    Poughkeepsie, New York, United States
  • Pfizer Investigational Site
    Rochester, New York, United States
  • Pfizer Investigational Site
    Troy, New York, United States
  • Pfizer Investigational Site
    Williamsville, New York, United States
  • Pfizer Investigational Site
    Eden, North Carolina, United States
  • Pfizer Investigational Site
    Greensboro, North Carolina, United States
  • Pfizer Investigational Site
    Greenville, North Carolina, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina, United States
  • Pfizer Investigational Site
    Reidsville, North Carolina, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina, United States
  • Pfizer Investigational Site
    Bellevue, Ohio, United States
  • Pfizer Investigational Site
    Cleveland, Ohio, United States
  • Pfizer Investigational Site
    Clyde, Ohio, United States
  • Pfizer Investigational Site
    Defiance, Ohio, United States
  • Pfizer Investigational Site
    Fostoria, Ohio, United States
  • Pfizer Investigational Site
    Middleburg Heights, Ohio, United States
  • Pfizer Investigational Site
    Orange Village, Ohio, United States
  • Pfizer Investigational Site
    Toledo, Ohio, United States
  • Pfizer Investigational Site
    Wauseon, Ohio, United States
  • Pfizer Investigational Site
    Westlake, Ohio, United States

Showing the first 100 of 147 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008 Dec 9;118(24):2506-14. doi: 10.1161/CIRCULATIONAHA.108.790733. Epub 2008 Nov 24. PubMed 19029466 ↗
  • Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007 Mar 29;356(13):1304-16. doi: 10.1056/NEJMoa070635. Epub 2007 Mar 26. Erratum In: N Engl J Med. 2007 Aug 23;357(8):835. Lasala, Gregory P [corrected to Lasala, Gabriel P]. PubMed 17387129 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2005
First posted
Aug 24, 2005
Start
Oct 2003
CompletionActual
Sep 2006
Last update
Dec 10, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00134173
Lead sponsor
Pfizer
First posted
Aug 24, 2005
Start date
Oct 2003
Completion
Sep 2006
Last update
Dec 10, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torcetrapib · Atorvastatin

Start the discussion